Sprintec and Peripheral t-cell lymphoma unspecified recurrent - a phase IV clinical study of FDA data

Summary:

We study 4,521 people who take Sprintec (ethinyl estradiol; norgestimate) or have Peripheral t-cell lymphoma unspecified recurrent. No report of Peripheral t-cell lymphoma unspecified recurrent is found in people who take Sprintec.

The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.

What is Sprintec?

Sprintec has active ingredients of ethinyl estradiol; norgestimate. It is often used in birth control. eHealthMe is studying from 4,397 Sprintec users. Check the latest studies of Sprintec.

What is Peripheral T-cell Lymphoma Unspecified Recurrent?

Peripheral t-cell lymphoma unspecified recurrent (peripheral t-cell cancer unspecified recurrent) is found to be associated with 8 drugs and 15 conditions by eHealthMe. Check the latest studies of Peripheral t-cell lymphoma unspecified recurrent.

On May, 17, 2026

No report is found.

Do you take Sprintec and have Peripheral t-cell lymphoma unspecified recurrent?

- Check whether Peripheral t-cell lymphoma unspecified recurrent is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Sprintec:

Sprintec (4,397 reports)

Peripheral t-cell lymphoma unspecified recurrent treatments and more:

Peripheral t-cell lymphoma unspecified recurrent (124 reports)

How severe was Peripheral t-cell lymphoma unspecified recurrent and when was it recovered:

Peripheral t-cell lymphoma unspecified recurrent in Sprintec

Expand to all the drugs that have ingredients of ethinyl estradiol; norgestimate:

Peripheral t-cell lymphoma unspecified recurrent and drugs with ingredients of ethinyl estradiol; norgestimate

Browse all side effects of Sprintec:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Peripheral t-cell lymphoma unspecified recurrent:

Peripheral t-cell lymphoma unspecified recurrent

Browse all the conditions that are associated with Peripheral t-cell lymphoma unspecified recurrent:

Peripheral t-cell lymphoma unspecified recurrent

How the study uses the data?

The study uses data from the FDA. It is based on ethinyl estradiol; norgestimate (the active ingredients of Sprintec) and Sprintec (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.